Assuntos
Objetivos , Liderança , Política Pública/legislação & jurisprudência , Ciência/legislação & jurisprudência , Ciência/organização & administração , Tecnologia/legislação & jurisprudência , Tecnologia/organização & administração , China , Mudança Climática , Comportamento Competitivo , Comportamento Cooperativo , União Europeia , Humanos , Pandemias , Política , Política Pública/economia , Política Pública/tendências , Parcerias Público-Privadas , Ciência/economia , Ciência/tendências , Ciências Sociais , Tecnologia/economia , Tecnologia/tendências , Estados UnidosRESUMO
This year's Lasker-Bloomberg Public Service Award goes to GAVI, the Vaccine Alliance, for providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease.
Assuntos
Cooperação Internacional , Vacinação/economia , Vacinação/história , Vacinas/história , Vacinas/provisão & distribuição , Criança , Saúde Global , História do Século XVII , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Programas de Imunização , Investimentos em Saúde , Pobreza , Medicina Preventiva/métodos , Vacinas/economiaRESUMO
Importance: Recent discussion has focused on questions related to the repeal and replacement of portions of the Affordable Care Act (ACA). However, issues central to the future of health and health care in the United States transcend the ACA provisions receiving the greatest attention. Initiatives directed to certain strategic and infrastructure priorities are vital to achieve better health at lower cost. Objectives: To review the most salient health challenges and opportunities facing the United States, to identify practical and achievable priorities essential to health progress, and to present policy initiatives critical to the nation's health and fiscal integrity. Evidence Review: Qualitative synthesis of 19 National Academy of Medicine-commissioned white papers, with supplemental review and analysis of publicly available data and published research findings. Findings: The US health system faces major challenges. Health care costs remain high at $3.2 trillion spent annually, of which an estimated 30% is related to waste, inefficiencies, and excessive prices; health disparities are persistent and worsening; and the health and financial burdens of chronic illness and disability are straining families and communities. Concurrently, promising opportunities and knowledge to achieve change exist. Across the 19 discussion papers examined, 8 crosscutting policy directions were identified as vital to the nation's health and fiscal future, including 4 action priorities and 4 essential infrastructure needs. The action priorities-pay for value, empower people, activate communities, and connect care-recurred across the articles as direct and strategic opportunities to advance a more efficient, equitable, and patient- and community-focused health system. The essential infrastructure needs-measure what matters most, modernize skills, accelerate real-world evidence, and advance science-were the most commonly cited foundational elements to ensure progress. Conclusions and Relevance: The action priorities and essential infrastructure needs represent major opportunities to improve health outcomes and increase efficiency and value in the health system. As the new US administration and Congress chart the future of health and health care for the United States, and as health leaders across the country contemplate future directions for their programs and initiatives, their leadership and strategic investment in these priorities will be essential for achieving significant progress.
Assuntos
Participação da Comunidade , Atenção à Saúde/organização & administração , Custos de Cuidados de Saúde , Prioridades em Saúde , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Poder Psicológico , Pesquisa Biomédica , Medicina Baseada em Evidências , Instalações de Saúde , Pessoal de Saúde/educação , Disparidades em Assistência à Saúde , Humanos , Reembolso de Incentivo , Estados UnidosRESUMO
Without a step change in the productivity of pharmaceutical research and development, it will be difficult to tackle the public health challenges facing societies worldwide. Publicprivate partnerships could play a key role in achieving this step change, but they need to be well designed and led.
Assuntos
Pesquisa Biomédica/métodos , Comportamento Cooperativo , Descoberta de Drogas/métodos , Parcerias Público-Privadas , Indústria Farmacêutica , Humanos , Saúde Pública/métodosAssuntos
Descoberta de Drogas , Pesquisa Translacional Biomédica , Animais , Ensaios Clínicos como Assunto , Indústria Farmacêutica/economia , Humanos , Terapia de Alvo Molecular , Pró-Proteína Convertase 9 , Pró-Proteína Convertases/genética , Pró-Proteína Convertases/metabolismo , Serina Endopeptidases/genética , Serina Endopeptidases/metabolismoAssuntos
Disciplinas das Ciências Biológicas/organização & administração , Biotecnologia/organização & administração , Indústria Farmacêutica/organização & administração , Investimentos em Saúde/organização & administração , Pesquisa Translacional Biomédica/organização & administração , Universidades/organização & administração , Relações Interinstitucionais , Estados UnidosRESUMO
The NIH, which originated from the Marine Hospital Laboratory of Hygiene (1887), was established as the national agency for medical research by President F. D. Roosevelt in 1944. The NIH rests on its independent, world-class peer review process and its distinctive scientific and public advisory structure. The two-fold mission of NIH is to define research priorities based on public health needs and to allocate funding. Eighty-four percent of the budget supports 300,000 extramural scientists and research workers at more than 3,000 universities. Only 16% of the budget is spent within the NIH itself (on administration and the 27 institutes and centers, including some 10,000 intramural scientists, that make up NIH today). The ecosystem of science and biotechnology connects NIH, the public, Congress, universities, the FDA, industry, and investors. The budget, which in 2007 was $29 billion, is submitted to Congress by the Director. The impact of biomedical research over the last 30 years is demonstrated by an increase in life expectancy anda decrease in death and disability from many diseases. Five evolving challenges in public health include acute conditions becoming chronic, the aging of the population, health disparities, emerging or re-emerging infectious diseases, and emerging non-communicable diseases (obesity, mental illness). Medical strategies must clearly be transformed for the 21st century. Molecular diagnosis of preclinical disease is the paradigm of the future: intervening before symptoms appear because the preclinical molecular events are known and because we have the ability to detect at-risk patients constitutes the "future paradigm of the 4 P's." Currently, the fundamental scientific barrier is our limited understanding of the complexity of biologic networks. New theoretical concepts are needed in this "hardware-to-software phase." Any roadmap for the acceleration of medical discovery will have to integrate new pathways, future research teams, and the restructuring of clinical research.
Assuntos
Pesquisa Biomédica/tendências , Humanos , National Institutes of Health (U.S.) , Dinâmica Populacional , Saúde Pública , Estados UnidosAssuntos
Financiamento Governamental , National Institutes of Health (U.S.)/economia , Apoio à Pesquisa como Assunto , Pesquisa Biomédica/economia , Pesquisa Biomédica/tendências , Orçamentos , Escolha da Profissão , Análise Custo-Benefício , Financiamento Governamental/economia , Financiamento Governamental/estatística & dados numéricos , Financiamento Governamental/tendências , Previsões , Revisão da Pesquisa por Pares , Pesquisadores/provisão & distribuição , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/estatística & dados numéricos , Apoio à Pesquisa como Assunto/tendências , Estados Unidos , Recursos HumanosRESUMO
National Institutes of Health (NIH) director Elias Zerhouni is pushing hard for innovation and the risk taking required to make major leaps in medicine. Fully attuned to cutting-edge work that crosses disciplines, he cites nanotechnology, clinical databases designed to answer research questions, systems biology, and an openness to radical ideas among his top priorities. The NIH director's job, he says, "is to have a vision." This requires leveraging NIH funding so that money is spent more wisely and has a cumulative effect on population health. Knowledge can be extracted from science, and health system transformation is made possible.